On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...
JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (ATHA – Research Report) today. The company’s shares closed yesterday at $0.75. According to TipRanks, Butler is an ...
Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on TipRanks’ ...
On Friday, Athira Pharma Inc (ATHA) stock saw a modest uptick, ending the day at $0.61 which represents a slight increase of $0.18 or 41.86% from the prior close of $0.43. The stock opened at $0.59 ...
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018.
Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow ...
As the U.S. stock market navigates a period of uncertainty with investors closely watching the presidential election and upcoming Federal Reserve interest rate decisions, opportunities continue to ...
Veena Nandakumar plays Meera, Sharaf U Dheen plays Biju, and Srinda plays Rema. Vijilesh Karayad, Shobi Thilakan, Varsha Ramesh, Nisthar Sait, Athira Patel, and Jinu Joseph are all supporting ...
This study, led by Athira Jayan, MD, The University of Texas MD Anderson Cancer Center in Houston, Texas, was published ...
based enterprise software company EnterpriseDB (EDB). Dallas spent almost 25 years at… Read More Athira Pharma’s stock plummeted nearly 70% Wednesday after a clinical trial testing its candida ...